Potential of Anti-Secretory and Cytoprotective Effect from Azadiradione as GERD Prevention
Abstract
Gastroesophageal Reflux Disease (GERD) is a pathological state due to stomach reflux within the esophagus, which causes necrosis of esophageal mucosa, resulting in erosions, ulcers, and other complications. GERD is still a growing global issue with 783.95 million cases worldwide in 2019. Although PPIs were used as medications to treat GERD, there were refractions and adverse effects to the patients. Azadiradione, terpenoids that can be found in A. indica and various plants, has potential as alternative H+/K+ ATPase inhibitor sources with its anti-secretory and cytoprotective activity. Some studies explain that there is also adverse effects of azadiradione. Further research are needed to determine alternative sources, safety dosage, usage duration, side effects, also drug-food or drug-drug interaction of azadiradione.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.